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ABSTRACT 
Introduction 
Smoking in pregnancy is a substantial public health issue, but, apart from nicotine replacement therapy 
(NRT), pharmacological therapies are not generally used to promote cessation. Bupropion and 
varenicline are effective cessation methods in non-pregnant smokers and this systematic review 
investigates their safety in pregnancy.   
Methods 
We searched MEDLINE, EMBASE, CINAHL and PsychINFO databases for studies of any design reporting 
pregnancy outcomes after bupropion or varenicline exposure. We included studies of bupropion used 
for smoking cessation, depression, or where the indication was unspecified. Depending on study design, 
quality was assessed using the Newcastle-Ottawa Scale or Cochrane Risk of Bias Tool. Most findings are 
reported narratively but meta-analyses were used to produce pooled estimates for the proportion of 
live births with congenital malformations and of the mean birthweight and gestational age at delivery 
following bupropion exposure.  
Results 
18 studies were included: two randomised controlled trials, eleven cohorts, two case-control studies 
and three case reports. Study quality was variable. Gestational safety outcomes were reported in 14 
bupropion and four varenicline studies. Meaningful meta-analysis was only possible for bupropion 
exposure, for which the pooled estimated proportion of congenital malformations amongst live-born 
infants was 1.0% (95% CI= 0.0-3.0%, I2= 80.9%, 4 studies) and the mean birthweight and mean 
gestational age at delivery was 3305.9g (95% CI= 3173.2-3438.7g, I2= 77.6%, 5 studies) and 39.2 weeks 
(95% CI= 38.8-39.6, I2= 69.9%, 5 studies) respectively. 
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Conclusions 
There was no strong evidence that either major positive or negative outcomes were associated with 
gestational use of bupropion or varenicline. PROSPERO registration number CRD42017067064. 
 
IMPLICATIONS 
We believe this to be the first systematic review investigating the safety of bupropion and varenicline in 
pregnancy. Meta-analysis of outcomes following bupropion exposure in pregnancy suggests that there 
are no major positive or negative impacts on the rate of congenital abnormalities, birthweight or 
premature birth. Overall, we found no evidence that either of these treatments might be harmful in 
pregnancy, and no strong evidence to suggest safety, but available evidence is of poor quality. 
 
INTRODUCTION 
Smoking in pregnancy is associated with increased risks of miscarriage, stillbirth, prematurity, low birth 
weight, perinatal morbidity and mortality1 and is a significant problem in developed countries where 
rates vary between 8 and 23% of pregnant women smoking in pregnancy.2-4 Children of smoking 
mothers are twice as likely to become smokers themselves5, so smoking in pregnancy and afterwards 
encourages the persistence of smoking across generations.6 Smoking  in pregnancy is declining in 
developed countries but remains highest amongst younger, socially disadvantaged women4 and the 
annual costs of managing the smoking-attributable maternal and infant disease can be substantial.7 
Studies have shown that pregnancy is the life event which most motivates smokers to attempt 
cessation, with around half of pregnant smokers attempting to quit.4 In addition, although the cost-
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efficacy of smoking cessation interventions in pregnancy is unclear8, stopping smoking in pregnancy is 
likely to save healthcare resources, both with respect to the health of the infant and in the wider 
context of preventing the perseveration of smoking in the next generation. Thus, promoting smoking 
cessation during pregnancy will substantially improve the health not only of the infant and mother but 
of their extended family and, in the longer term, will contribute to reducing the substantial healthcare 
cost of smoking-related diseases. However, compared to those available for non-pregnant smokers, 
relatively few effective cessation interventions can be used in pregnancy and nicotine replacement 
therapy (NRT) is the only drug treatment used to any extent.9 The UK National Institute for Healthcare 
and Excellence (NICE) recommends using NRT, believing it safer that continued smoking in pregnancy. 
However, in pregnancy NRT has at best only a borderline significant effect on cessation (RR 1.28, 95% CI 
0.99-1.66)10 and this lower efficacy, compared to use outside of pregnancy, is probably caused by poor 
adherence to NRT.11  
If they were considered sufficiently safe, other effective cessation pharmacotherapies, varenicline and 
bupropion, could also be tried in pregnancy. Varenicline is well tolerated12 and probably more effective 
than other cessation treatments;13 animal research suggests it is not teratogenic.14  Similarly, bupropion 
is an effective smoking cessation aid which approximately doubles non-pregnant smokers chances of 
stopping.15 If varenicline or bupropion were to be proven effective for pregnant smokers, the health 
benefits which would accrue from stopping smoking would very likely outweigh any minor adverse 
effects. Consequently, to help assesses whether experimental studies might be ethical, we review 
evidence for the safety of varenicline and bupropion in pregnancy.   
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METHODS  
A study protocol was registered16 and the review adhered to Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis (PRISMA) guidelines.17  
Inclusion Criteria 
We included studies of any design which reported adverse pregnancy outcomes experienced by 
mothers, foetuses or infants following use of varenicline or bupropion in pregnancy.  
Exclusion criteria 
We excluded studies which presented no empirical data and those in which interventions combined 
bupropion or varenicline with other cessation pharmacotherapies.  
Search Strategy 
We searched the MEDLINE, EMBASE, CINAHL and PsychINFO databases and hand-searched reference 
lists from reviews and included papers. We also searched for ongoing and unpublished studies at: 
www.gsk-clinicalstudyregister.com; clincialtrials.gov; www.who.int/trialsearch; www.controlled-
trials.com/isrctn; and www.ukctg.nihr.ac.uk. As bupropion and varenicline were licensed and became 
available relatively recently, we sought studies published from 1990 until 25th May 2017 with no 
language restrictions. Search terms relating to pregnancy were developed from those used in a 
Cochrane review10 and were combined with qualitative terms relating to smoking, varenicline or 
bupropion. The protocol also states that we intended to include studies in which women used ‘dual’ 
nicotine replacement therapy (NRT)16, however only two such studies were identified, and therefore we 
retrospectively decided that they should not be reviewed separately from other NRT studies (e.g. those 
investigating ‘mono’ NRT).  
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Data Extraction 
Titles and abstracts were screened by the lead reviewer, retrieving complete manuscripts if necessary to 
decide on inclusion. All articles were independently assessed by two reviewers to confirm inclusion in 
the review, with adjudication via a third reviewer when agreement was not met. The following data was 
extracted by the lead reviewer and checked by a second reviewer, with any discrepancies resolved by a 
third reviewer: aims and design, numbers of participants, outcomes, data collection, analysis methods 
and findings. Where studies reported interim analyses, further details were requested from authors. 
Quality Assessment 
Quality assessment was performed using Newcastle-Ottawa Scales18 for cohort or cross-sectional studies 
and the Cochrane Risk of Bias Assessment for RCTs.19 Initial assessment was made by the lead reviewer 
and checked by a second reviewer, and discrepancies resolved by a third reviewer. Where a trial had 
already been quality-assessed for a Cochrane review, we used this published assessment. 
Data Synthesis 
A priori, we anticipated that review studies might be so diverse that meaningful data synthesis could be 
challenging. Hence, we planned making final decisions on whether or not meta-analyses were possible 
once data extraction was finished, and outcomes of this deliberation are reported alongside review 
findings. If performed, we anticipated that meta-analyses would be conducted in Stata version 1420 
using a random effects DerSimonian and Laird model to generate pooled means and 95% confidence 
intervals with heterogeneity quantified by the I2 statistic.21  Rather than not pool studies in the presence 
of a high I2 value, we planned to present this statistic alongside meta-analysis findings to inform the 
reader of the extent to which pooled estimates should be treated cautiously. 
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RESULTS  
We identified 772 studies (1,053 including duplicates); no ongoing trials were identified from registries 
and no completed, unpublished studies were identified from pharmaceutical company databases. We 
identified 30 articles for retrieval in full, with 18 being included in the review (Figure 1); study details 
and outcomes are shown in Supplementary Material Table 1. 
Study Design, Outcome Measures and Quality Assessment 
Included studies comprised two randomised controlled trials (RCTs)22,23, eleven cohort studies24-34, two 
case-control studies35,36, and three case reports.37-39 Maternal or foetal adverse outcomes were reported 
in fourteen bupropion22-31,36-38 and four varenicline studies.32-34,39 Although bupropion can be used as an 
anti-depressant or for smoking cessation, only two RCTs specified that bupropion had been prescribed 
for smoking cessation.22,23 The three observational studies evaluating varenicline exposure did not 
explicitly state that varenicline was used for smoking cessation, but all discussed its sole indication as a 
cessation pharmacotherapy.32-34 
Congenital malformations were reported in eight studies (six following bupropion27-30,35,36 and two 
following varenicline33,34); reported malformation classification systems are described in Supplementary 
Material Table 1. Birthweight and gestational age at delivery were reported in five bupropion studies22-
24,26,27. Other outcomes included: foetal loss or stillbirth25,27,30,32,34; foetal length or head 
circumference22,23; preterm birth22-24; maternal medication adverse effects23,25,39; and pre-eclampsia.31  
An overview of reported outcomes is shown in Table 1.  
Study quality was variable (Table 2) with seven of the eleven observational studies assessed as of low 
methodological quality (score of <7)25,26,29,30,32-34; the three case reports were considered to provide only 
low-quality evidence.37-39 
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Potential for Meta-Analyses 
From the distribution of outcomes across studies and study designs (Table 1) it was clear that the few 
studies investigating varenicline were so different in design and outcome measurement that meaningful 
meta-analyses was not possible. For bupropion studies, meta-analyses investigating effects on 
congenital malformation, mean birthweight, and mean gestational age at birth were considered feasible 
and were undertaken by combining studies or study arms with sufficiently similar designs. For the meta-
analysis investigating effects of bupropion exposure on congenital malformations, we included only 
cohort studies.27-30 For birthweight and gestational age at birth meta-analyses, we pooled data from 
bupropion-exposed arms in cohort studies24,26,27 and RCTs22,23  to determine the mean value associated 
with each outcome.   
 
Bupropion 
Congenital Malformations 
Six studies, four cohort27-30and two case control studies35,36, reported congenital malformations. Cohort 
studies included 3,376 pregnancies (Figure 2) and from these studies the pooled estimate for the  
percentage of congenital malformations amongst live-born infants exposed to bupropion at any point 
during gestation was 1.0% (95% CI = 0.0-3.0%, I2 = 80.9%) (Figure 3a). As individual studies classified 
congenital malformations in different ways (Supplementary Material Table 1), we accepted the presence 
or absence of malformations was as defined within each study and no attempt was made to derive a 
single classification system applied to all studies. Pregnancies which ended in stillbirth, miscarriage, 
intra-uterine foetal death or termination were excluded from the analysis, so we defined the proportion 
of pregnancies with congenital malformations as follows: 
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𝑃𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑎𝑛𝑦 𝑐𝑜𝑛𝑔𝑒𝑛𝑖𝑡𝑎𝑙 𝑚𝑎𝑙𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛 =
number of live born infants with a malformation
total number of live born infants exposed 𝑖𝑛 𝑢𝑡𝑒𝑟𝑜
  
The two case-control studies had conflicting results.35,36  Both used National Birth Defects Prevention 
Study (NBDPS) criteria40 to classify congenital cardiac defects;  overall, Alwan found no evidence that  
maternal bupropion exposure in pregnancy increased infants’ risks of developing congenital cardiac 
defects (adjusted odds ratio 1.4, 95% CI = 0.8-2.5).35 Alwan did however, report an increased risk of left 
outflow tract cardiac defects (adjusted odds ratio 2.6, 95% CI = 1.2-5.7) which was not found by Louik36 
(adjusted odds ratio 0.4, 95% CI = 0-2.4). Louik investigated the risk of developing eight different cardiac 
defects following bupropion exposure but did not attempt to estimate the overall risk of any cardiac 
defect and reported an increased risk of ventricular septal defects (adjusted odds ratio 2.9, 95% CI = 1.5-
5.5) which was not found by Alwan (adjusted odds ratio 1.2, 95% CI = 0.5-3.4). Louik found no increased 
risks for other sub-categories of cardiac defects following bupropion exposure. 
 
Birthweight 
Two RCTs (combined n = 35) found no significant differences in birthweight between bupropion or 
placebo groups (Supplementary Material Table 1) but both will likely have been under-powered to 
detect clinically-significant differences.22,23 One controlled cohort study conducted in smokers found 
significantly higher mean birthweights amongst infants born after exposure to bupropion (3315.9g, SD 
553.3, n=72) compared to those who smoked and used no treatment (2943.5g, SD 733.5, n=900, 
p<0.05).24 However, this finding was not replicated in two other bupropion cohort studies.26,27 Meta-
analysis of the 262 pregnancies in bupropion-exposed arms from cohorts and RCTs gives a pooled 
estimate for mean birthweight amongst infants exposed to bupropion of 3305.9g (95% CI = 3173.2-
3438.7g, I2 = 77.6%, n=262) (Figure 3b). 
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Gestational Age at Delivery 
Of five studies reporting gestational age at birth, two were RCTs22,23and three cohort studies.24,26,27 No 
significant differences were found between trial groups within the likely under-powered RCTs or 
between exposure groups in two of the cohort studies.26,27 However, one cohort study found that 
infants born after bupropion exposure had a significantly higher mean gestational age at birth (39.1 
weeks, SD 1.3, n=72) compared to non-exposed infants born to smokers (37.5 weeks, SD 3.3, n=900, 
p<0.05).24 The pooled estimate for mean gestational age at delivery in the five studies which included 
260 pregnancies was 39.2 weeks (95% CI 38.8-39.6, I2 = 69.9%) (Figure 3c).  
 
Foetal Loss  
Three cohort studies reported foetal loss following bupropion exposure25,27,30, with only one study 
including control group data.27  
The GlaxoSmithKline “Bupropion Pregnancy Registry” cohort reported data from 994 prospectively-
registered pregnant women (featuring 1005 monitored foetuses) following gestational bupropion 
exposure. Following first trimester bupropion exposure there were 669 live births, three foetal deaths 
occurring at or later than 20 weeks gestation, 38 induced abortions, and 96 spontaneous pregnancy 
losses occurring before 20 weeks. Following second trimester exposure there were 145 live births, one 
induced abortion and one spontaneous pregnancy loss and after bupropion exposure in the third 
trimester there were 51 live births and one foetal death. 603 prospectively-registered pregnancies were 
either lost to follow-up or pending delivery when the register closed, resulting in a loss of outcome 
data.30 
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One study found significantly higher rates of spontaneous abortions (p=0.009) and therapeutic abortions 
(p=0.015) in a bupropion cohort compared with those exposed to ‘non-teratogenic’ agents.27 A small 
uncontrolled, cohort study of 12 pregnancies, reported five live births, two therapeutic terminations (no 
explanation of reasons for termination given), one intrauterine death, and four cases that were lost to 
follow-up following gestational bupropion exposure.25   
 
Varenicline 
Four varenicline studies reported relevant adverse outcomes; three cohort studies32-34 and one case 
report study.39 No study explicitly stated that such exposures were unintentional, though this was 
probably the case as there were no smoking cessation studies and varenicline has no therapeutic 
indications in pregnancy. 
Richardson reported outcomes and congenital malformations following exposure to varenicline in 
pregnancy (n=89) in a study which compared pregnant women exposed to non-teratogenic agents 
(n=267) with those exposed to either NRT or bupropion (combined group, n=267). As determined by the 
EUROCAT classification system for congenital malformations41, seven infants (7.87%) in the varenicline 
group were reported to have a congenital malformation; two of which were “major” and five “minor”. 
No significant between-group differences were found in malformation rates.34  
Another cohort study reported malformation rates in infants both exposed (4.3%, n=254) and not 
exposed to varenicline in utero and also in those exposed to maternal smoking during gestation (4.2%, 
n=5296), and those exposed to neither varenicline nor smoking in utero (4.2%, n=656,139). Rates 
appeared similar but no statistical comparison of groups was undertaken.33  
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One uncontrolled cohort of 23 varenicline-exposed pregnancies reported 14 live full-term births (61%), 
two live pre-term (<37 weeks gestation) births (9%), four terminations of pregnancy (17%), two 
spontaneous or missed abortions (9%) and one ectopic pregnancy (4%). Within this cohort five foetal 
adverse events were reported, as shown in Supplementary Material Table 1.32 
One case report described a normal pregnancy, delivery and infant health until six months following 
gestational varenicline exposure for four weeks from the last menstrual period.39  
 
DISCUSSION  
We believe this is the first systematic review investigating the safety of bupropion and varenicline in 
pregnancy. We found no evidence that either of these treatments might be harmful in pregnancy but 
available evidence is of poor quality and there is also no strong evidence to suggest safety. Most studies 
investigated outcomes following bupropion exposure and pooled estimates for birthweight, gestation at 
birth and congenital abnormality rates do not suggest that any of these outcomes are adversely 
affected. However, estimates’ confidence intervals were relatively wide and more data would be 
required to improve precision. Far fewer studies investigated outcomes following varenicline exposures 
and overall there is probably insufficient evidence to make firm conclusions about the safety on any of 
either therapy in pregnancy.  
This study has some limitations. Relatively few studies were eligible for inclusion reflecting a paucity of 
relevant data and the majority of those in the review were small and observational, with only two 
RCTs.22,23 This restricted assessment of potential causal relationships. Included studies generally had low 
methodological quality; some are case reports37-39 or cohort studies which lack control groups.25,30,32 
Relatively few studies reported similar outcomes, restricting the potential for meta-analysis and, where 
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these were conducted, heterogeneity was high, presumably due to differences between study designs 
and comparator groups; this heterogeneity means that pooled estimated need to be treated with 
caution. As there were so few studies investigating bupropion specifically for smoking cessation 
purposes22,23, we combined those which stated explicitly that bupropion had been used for smoking 
cessation and also those where the purpose of bupropion use was unspecified and this could have been 
prescribed for either smoking cessation or depression. Consequently, some of the data in our meta-
analyses will have come from non-smokers who would be expected to have better birth outcomes than 
smokers.  As the evidence regarding the safety of varenicline during pregnancy is sparser than that for 
bupropion, with safety data identified in only four studies32-34,39, this review predominantly focuses on 
bupropion. Because of the low quality designs (e.g. uncontrolled32) and complex comparator groups (e.g. 
pregnant women exposed to non-teratogenic agents or those using either NRT or bupropion as a single 
group), no conclusion as to the safety of varenicline can be made.34   
A strength of this review is its novelty and systematic approach. By including studies with any design it is 
likely we have identified the majority of available safety evidence. Additionally, the rigorous quality 
assessment indicates that further investigation of the safety of pharmacotherapy during pregnancy is 
required. We have aimed to maximise use of available data and believe we have made the best use of 
this whilst also being sensitive to the limitations inherent in empirical studies’ designs.    
Our pooled estimate for the proportion of congenital malformations in live-born infants following 
gestational bupropion exposure (1%) is similar to those reported in comparable populations. From 2011-
2015 EUROCAT, a European network of population-based registries, reported a congenital abnormalities 
rate of 2.5% amongst live births, foetal deaths, stillbirths, and terminations for foetal abnormalities.42 In 
addition, the MACDP (Metropolitan Atlanta Congenital Defects Program) determined the rate in five 
central counties of Atlanta between 1968 and 2003, to be 2.67%.43  Included papers reported only 
abnormalities within live-born infants; however population-based registries generally include 
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pregnancies in which the fetus dies before term. As abnormalities are less likely to be present in live-
born infants, the 1% review-derived rate may underestimate prevalence in all pregnancies and the 
interpretation of our data is not completely straightforward. Despite this, it is reassuring that the upper 
95% CI for the estimate (3%) is close to population estimates; further studies would increase the 
precision of this estimate and possibly provide further reassurance that congenital abnormality rates are 
not higher after bupropion exposure. 
Although 95% confidence intervals are consistent with wide range of values, the meta-analysis derived 
point estimate for mean birthweight following bupropion exposure 3305.9g (95% CI: 3173.2-3438.7g) 
was similar to the population average of the countries in which the studies reporting this outcome were 
conducted. Studies included in the birthweight meta-analysis were predominantly North American and 
only one was UK-based.27 Population-based data show that the average birthweight for those born 
between 37 and 41 weeks of gestation in the U.S.A. in 2005 was 3389g (SD 466)44, and in 2009 the mean 
birthweight of Canadian babies was 3364g.45 Calculating the effects of bupropion on birthweight is also 
complicated by the known reduction in birthweight associated with maternal smoking; for example, one 
large study of 3,338 mothers reported an adjusted birthweight deficit within babies born to active 
smokers averaging 226 grams.46 Four of the studies contributing to the pooled estimate for birthweight 
following bupropion exposure included only pregnant smokers22-24,26 and the remaining study controlled 
for the effects of smoking by matching study groups by smoking status.27 None of the review studies 
reported a mean birthweight within the bupropion-exposed groups that was significantly less than their 
control groups22-24,26,27; in 4 studies, birthweights were higher in the bupropion cohorts22,23,26,27, and in 
one study this finding was statistically significant.24 The latter study reported increasingly heavier 
birthweights between pregnant smokers who used no cessation pharmacotherapy, who used a nicotine 
patch, and who used bupropion, with rates of smoking cessation during pregnancy of 0%, 79% and 81%, 
respectively. The high rates of smoking cessation in the bupropion-exposed cohort in this study may 
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have been the driving factor behind the higher birthweight within the group, rather than being 
associated with bupropion pharmacotherapy itself, but this nonetheless is a beneficial outcome.  
We calculated the pooled mean gestational age at delivery following bupropion exposure as 39.2 weeks 
(95% CI 38.8-39.6), as shown in Figure 3. This is comparable to the normal 40 week gestation and 
clinically insignificant. When assessing the studies which compared bupropion-exposed infants to 
pregnant smokers not using bupropion, there was also no evidence of a significant negative effect. One 
study found the mean gestational age at birth for infants born to pregnant smokers using bupropion was 
significantly later than that of pregnant smokers using nicotine patch or no cessation pharmacotherapy, 
which may be in some part associated with higher smoking cessation rates within the bupropion 
exposed group.24 The remainder of the studies either found no significant differences in mean 
gestational age at delivery22,26 or reported similar findings between exposed and non-exposed groups 
with no determination of significance levels.23,27  
Whilst this review demonstrates the paucity of safety evidence, the authors are aware of several 
ongoing studies which will provide further insight. These include the Australian “Smoking MUMS Study”, 
a population-based investigation to further assess the safety of these agents in pregnancy47, two 
investigating bupropion48,49, and one of varenicline.50  
 
CONCLUSION 
This review finds no conclusive evidence for the safety of gestational use of bupropion or varenicline. 
Pooling the limited available evidence suggests that bupropion has no major positive or negative 
impacts on the rates of congenital abnormalities, birthweight or premature birth.  
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Figure 1. PRISMA flowchart of included studies 
 
 
Figure 2. Overview of pregnancies included in meta-analysis of congenital malformations following 
bupropion exposure 
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Figure 3a: Proportion of congenital malformations following bupropion exposure 
 
Figure 3b:  Mean birthweight following bupropion exposure 
 
Figure 3c:  Mean gestational age at delivery following bupropion exposure  
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Table 1. Overview of reported outcomes by study 
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Paper Drug of Interest 
Alwan  2010 Bupropion   
         
Berard  2016 Bupropion 
 
  
  
  
   
Boshier  2003 Bupropion 
   
 
   
 
  
Chan 2005 Bupropion 
 
  
       
Chun-Fai-Chan 2005 Bupropion     
      
Cole 2007 Bupropion  
         
Einarson 2009 Bupropion  
         
Gisslen 2011 Bupropion 
      
 
   
GSK 2008 Bupropion  
  
 
      
Leventhal 2010 Bupropion 
      
 
   
Louik 2014 Bupropion  
         
Nanovskaya 2017 Bupropion 
 
  
 
   
 
 
 
Palmsten 2013 Bupropion 
         
 
Stotts 2015 Bupropion 
 
  
 
 
 
   
 
Harrison-Woolrych 2013 Varenicline 
   
 
  
 
   
Kaplan 2014 Varenicline 
       
 
  
Olsen 2015 Varenicline  
         
Richardson 2017 Varenicline  
  
 
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Table 2. Quality Assessment of Included Studies  
COHORT STUDIES – NEWCASTLE-OTTAWA SCALE 
 Selection (Max 4) Comparability (Max 2) Outcome (Max 3) TOTAL (Max 9) 
Berard, 2016     
Palmsten, 2013     
Chun-Fai-Chan, 2005     
Cole, 2007     
Einarson, 2009     
Boshier, 2004  0   
Chan, 2005     
Harrison-Woolrych, 2013  0   
Olsen, 2015  0   
GlaxoSmithKleine, 2008  0   
Richardson, 2017  0   
CASE-CONTROL STUDIES – NEWCASTLE-OTTAWA SCALE 
 Selection (Max 4) Comparability (Max 2) Exposure (Max 3) TOTAL (Max 9) 
Alwan, 2010     
Louik, 2014     
RANDOMISED CONTROLLED TRIALS – COCHRANE RISK OF BIAS 
 Random sequence 
generation 
Allocation 
concealment 
Blinding of participants 
& personnel 
Blinding of outcome 
assessment 
Incomplete 
outcome data 
Selective outcome 
reporting 
Nanovskaya, 2017 Low risk Unclear Low risk Low risk High risk High risk 
Stotts, 2015* Low risk Unclear Low risk Low risk High risk High risk 
CASE REPORTS 
Gisslen, 2011 High risk by design, unblinded assessments 
Kaplan, 2014 High risk by design, unblinded assessments 
Leventhal, 2010 High risk by design, unblinded assessments 
 
*Quality assessment for Stotts 2015 as assessed in the Cochrane Review “Pharmacological interventions for promoting smoking cessation during pregnancy” (2015)10 
 
